Remix Investor Deck Reveals 43% ORR for Lead Asset, $100M PIPE, and 92.6% Dilution for Passage Holders
PASG sits 49% above its 52-week low of $3.29 on light trading volume (0.1× avg).
Summary
Remix's investor presentation reveals compelling Phase 1 data for REM-422 in ACC (43% ORR), a $100M PIPE, and a 92.6%/7.4% pro forma ownership split that confirms massive dilution for Passage Bio shareholders.
Key Events · M&A and Partnerships · PASG
-
REM-422 Phase 1 Data Revealed
43% ORR and 100% disease control rate in MYB biomarker-positive ACC patients at the recommended Phase 2 dose, with durable responses lasting up to 2+ years. Historical ORR for available therapies is 0–15%.
-
$100M PIPE Financing Confirmed
An oversubscribed $100 million concurrent private placement will fund the combined company into H1'28, past the mid-2027 ACC data readout and potential NDA submission as early as H2'27.
-
Extreme Dilution for Passage Shareholders
Pro forma ownership split of 92.6% Remix / 7.4% Passage post-financing means existing Passage Bio stockholders will own just 7.4% of the combined entity — a near-total wipeout of their stake.
-
Remix Takes Full Control
The combined company's nine-member board will be entirely designated by Remix, and Remix management will operate the pro forma company, confirming this is a reverse merger with Remix in control.
Analysis · PASG · Life Sciences
The Remix Therapeutics investor presentation filed by Passage Bio provides the first detailed look at the combined company's lead asset REM-422, showing a 43% objective response rate in adenoid cystic carcinoma — a cancer with no approved therapies and historical response rates of 0–15%. The data support a potentially registrational Phase 2 trial already >60% enrolled, with a $600M+ U.S. market opportunity. Critically, the deck confirms a $100 million oversubscribed PIPE financing alongside the merger, extending the pro forma cash runway into the first half of 2028. For existing Passage Bio shareholders, the pro forma ownership split of 92.6% Remix / 7.4% Passage quantifies the extreme dilution — a near wipeout — but the merger is the only path to value after Passage's going-concern warning and 75% workforce reduction earlier this year. The all-Remix board and management team underscore that this is effectively a Remix takeover using Passage's Nasdaq listing.
At the time of this filing, PASG was trading at $4.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8M. The 52-week trading range was $3.29 to $20.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.